HOUSTON, Oct. 12, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, today highlighted a new segment of
"Behind the Mystery" focused on glioblastoma from The Balancing Act
airing on Lifetime TV. The segment, live this morning, follows the
unique story of a glioblastoma patient and clinical insights
regarding the rare and difficult-to-treat disease from Dr.
Sigmund Hsu, a member of the
Scientific Advisory Board of CNS Pharmaceuticals. A re-airing of
the segment is planned for October 23,
2020.
"It is encouraging to see the Balancing Act feature bring
awareness to such a devastating disease. Glioblastoma is one of the
most aggressive primary brain cancers in adults, with approximately
13,000 new patients diagnosed each year in the U.S.—the highest
diagnosis rate of all malignant brain tumors. At CNS, we are
committed to our development efforts in glioblastoma," said
John Climaco, CEO of CNS
Pharmaceuticals.
To view the segment and hear the story, visit
thebalancingact.com/behind-the-mystery-glioblastoma-GBM.
CNS Pharmaceuticals provided support for the production of
this Balancing Act segment.
About The Balancing Act
The Balancing Act is a morning show created and produced
by BrandStar that offers sensible solutions and essential
information in a fun, entertaining format; providing resources to
help people do life better. The Balancing Act features everything
from delicious recipes, style makeovers and dream getaways to
parenting tips and the latest news in health and wealth. Tune in to
The Balancing Act weekdays at 7:30 a.m.
(ET/PT) on Lifetime®, and find all previously aired episodes
on TheBalancingAct.com.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary
and metastatic cancers of the brain and central nervous system.
Its lead drug candidate, berubicin, has been studied in a
completed Phase 1 clinical trial in malignant brain tumors.
By the end of 2020, CNS expects to commence a Phase 2 clinical
trial of berubicin for the treatment of glioblastoma multiforme
(GBM) in the U.S., while a sub-licensee partner undertakes a Phase
2 trial in adults and a first-ever Phase 1 trial in pediatric GBM
patients in Poland. Its second drug candidate, WP1244, is a
novel DNA binding agent that has shown in preclinical studies that
it is 500 times more potent than the chemotherapeutic agent
daunorubicin in inhibiting tumor cell proliferation.
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Company to
initiate its Phase 2 trial in the fourth quarter of this year.
These statements relate to future events, future expectations,
plans and prospects. Although CNS believes the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including those discussed in the Company's SEC
filings, including under the heading "Risk Factors" in the Form S-1
filed on October 7, 2019. Any
forward-looking statements contained in this press release speak
only as of its date. CNS undertakes no obligation to update any
forward-looking statements contained in this press release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-highlights-new-balancing-act-segment-on-glioblastoma-airing-on-lifetime-tv-301149947.html
SOURCE CNS Pharmaceuticals, Inc.